The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Gje306... in my experience it can take a few weeks before starting chemo...and as you say some patients may be nervous but they are not getting a new drug...they are getting dox in a new carrier which has already show it targets the dox at the tumour and substantially reduces the serious side effects.
It's more likely difficult to find patients that meet all the strict trial criteria...which is often the case with trials znd reason they can take longer than initially thought.
Gje306...the have said readouts are due late Q2..so June 2024. As I've said before they probably got all the screening sorted and were just waiting for the fundraiser to complete. Now they have to get their skates on...
Significant Newsflow
The Company is anticipating the progression of its clinical development and research stage programmes to important value inflection points across 2024 and 2025, which includes key deliverables for the pre|CISIONTM pipeline:
· AVA6000:
o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;
o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and
o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.
· AVA3996:
o Complete IND enabling studies and submit IND/CTA application in Q4 2024/Q1 2025; and
o Initiate Phase 1a dose escalation study in the first half of 2025.
· pre|CISION? pre-clinical pipeline:
o Next clinical candidate to be selected Q1 2025;
o Tumour microenvironment activated drug conjugate clinical candidate to selected in the second half of 2025; and
o Further expand pipeline;
PL75....'Suspect they're all at it. Sitting about waiting for AIM companies to give them the chance to make a few bob at PIs expense'...
Errrrr! I can't believe you've only just realised that's why II's love fundraisers so much...for this very reason that's why I was , and still am, hoping that the European Speciality Fund is the likes of Medicxi because they would be in for the long haul.
Did someone say there was a 40 day rule which ends on 9 April?
So let's see what that brings in the way of news or is it just a postr of what we've already been told.
DTW...' the majority of fund managers do not have an understanding of the science at AVCT.'...they know very little about most of the companies they are invested in. Unfortunately well researched PI's tend to think II's must be the same or that they may know more. In my experience this s not the case unless they've gone Inside and even the information the might get then is put out to the wider market in a matter of days/weeks at the most.
I'd even bet some of the information put out by Avacta's partners doesn't even hit the desks in Avacta. We've had several postings on here which would have made nice news items for Avacta and we've seen nothing. They can't blame an NDA because the information was made public knowledge by the said company.
BV...I think if they changed him and got someone in who really knew how to communicate then I think the problem might be much improved. As it stands we now have almost two years worth of financing. I'm not sure how long it will take the retail investors to get their new shares but that could be a reason for no news yet.
Experience
Avacta
9 years 10 months
Group Communications Director
Dec 2020 - Present 3 years 4 months
United Kingdom
Leading on corporate communications for Avacta Group, a UK based clinical stage biotech and diagnostics company.
• Creation and execution of Group communications strategy.
• Support senior leadership with considered counsel on reputation related matters and leading issues preparations and response.
• Managing partnerships with a range of advisors and agencies.
• Investor relations and working within the regulatory framework of being a publicly listed company.
• Media relations
Disagree BV...this is the guy they need to get rid of...
https://uk.linkedin.com/in/michaelvinegrad
Don't any of you read RNS's...it's all in the 28 Feb Fundraising RNS. Due to the Placing/Fundraiser the Heights pricing will be recalculated and the calculation is all in there. Again, this was also all mentioned in the initital Heights deal RNS whereby if the SP dropped by a certain amount below their 95p the price would be recalculated....bla bla bla...
Https://avacta.com/wp-content/uploads/2023/06/FY22-ARA-Final-Print-Version.pdf
Geez...you could have worked out the companies cash position yourselves by reading the accounts. Don't blame others for what they choose to do with their shares.
And for those worried about share options...again read the accounts...AS let one lot lapse and has a bunch which are exciserable (and so does EF and TG) but have chosen not to.
Unlike some on here, there are not in it to make a quick buck...
BV...'Do you want to bet on that?' No, because I did not define what the clear update might be about so you will only try and wriggle out of the bet if the update does not contain what you want it to...Ha ha....!!!
Notrex...fundraising never goes down well with PIs sotting on a big paper loss. When you get large fundraisers bring large amounts of new shares to the market the SP will always suffer. I'm sure the company has been inundated with EMails re comms etc. Once the company gets out from under any comms restrictions they may be under, I'm sure we will get a very clear update.
Right now it's not worth bursting any more blood vessels unless you're here to further try and disrupt this BB which I'm sure you're not...are you? 🫣